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Abstract
Background: AIDS is one of the most devastating diseases in human history. Decades of studies have revealed host factors
required for HIV infection, indicating that HIV exploits host processes for its own purposes. HIV infection leads to AIDS as
well as various comorbidities. The associations between HIV and human pathways and diseases may reveal non-obvious
relationships between HIV and non-HIV-defining diseases.
Principal Findings: Human biological pathways were evaluated and statistically compared against the presence of HIV host
factor related genes. All of the obtained scores comparing HIV targeted genes and biological pathways were ranked.
Different rank results based on overlapping genes, recovered virus-host interactions, co-expressed genes, and common
interactions in human protein-protein interaction networks were obtained. Correlations between rankings suggested that
these measures yielded diverse rankings. Rank combination of these ranks led to a final ranking of HIV-associated pathways,
which revealed that HIV is associated with immune cell-related pathways and several cancer-related pathways. The
proposed method is also applicable to the evaluation of associations between other pathogens and human pathways and
diseases.
Conclusions: Our results suggest that HIV infection shares common molecular mechanisms with certain signaling pathways
and cancers. Interference in apoptosis pathways and the long-term suppression of immune system functions by HIV
infection might contribute to tumorigenesis. Relationships between HIV infection and human pathways of disease may aid
in the identification of common drug targets for viral infections and other diseases.
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Introduction
Acquired immunodeficiency syndrome (AIDS) is a devastating
disease that has afflicted the human species for decades. Despite
the enormous amount of effort and resources devoted to its study,
a cure for AIDS has not yet emerged. AIDS is caused by human
immunodeficiency virus (HIV). Similar to other diseases caused by
pathogens, various human pathways must be perturbed or even
hijacked to serve the purposes of the HIV virus. Indeed, hundreds
of human host factors have been identified as necessary during
viral infection and replication [1–3]. Thousands of protein-protein
interactions between HIV and human host proteins have been
reported in the literature [4].
Certain diseases are known to be associated with HIV infection.
For example, the association between HIV/AIDS and lympho-
ma/Karposi’s sarcoma has been recognized since the discovery of
HIV [5]. Tuberculosis, hepatitis B/C, and other diseases are
known comorbidities of HIV infection [6,7], and HIV infection is
even associated with neurocognitive disorders [8]. These findings
have led us to enquire into the human pathways and diseases that
are associated with AIDS and the molecular mechanisms behind
these associations.
Previous research has attempted to elucidate host-pathogen
interactions through protein-protein interactions. Interactions
between human proteins and several pathogens, including Hepatitis
C virus [9],Epstein-Barrvirus [10],influenzavirus[11], and several
strains of bacteria [12], were identified systematically. These studies
suggested that interactions between humans and pathogens (viruses
or bacteria) are extensive and prevalent. Several studies have also
attemptedtoidentifyhuman biological processesthat areinfluenced
or perturbed by viruses [13,14]. These studies depicted human-
pathogen interactions from a global perspective by pooling
interactions with different pathogens and identifying common
mechanismsplayingimportantrolesinviralandbacterialinfections.
Onestudyspecifically analyzedtheinteractionsbetweenHIV-1and
human proteins [15] and found that HIV targeted proteins that
were not involved in human diseases listed in the Online Mendelian
Inheritance in Man (OMIM).
To study the functional enrichment of genes (the association of
genes with a specific function or pathway), gene set enrichment
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e34240analysis (GSEA) and its derivatives are widely adopted [16,17]. In
GSEA, genes are ranked by their correlations with phenotypes and
an enrichment score (ES) is calculated to estimate whether genes
from a gene set are clustered in the extreme regions (the bottom or
top) of the ranked list. Some studies have applied GSEA to
network/pathway analysis as well. For example, proteins in a
protein-protein interaction network can be ranked by their degrees
or by other centrality scores [13]. Enrichment scores for pathways
or other gene sets can be calculated based on the ranks and
clusters of genes from these pathways. GSEA can also be applied
to the evaluation of HIV/pathway associations, but genes must be
ranked by their relatedness with HIV first. The selection of
ranking criteria would impact the results of enrichment analysis.
In this work, we explored links between HIV infection and other
human pathways of disease through several approaches: investi-
gating the overlap of human genes involved in AIDS and other
pathways, examining recovered human-HIV interactions in other
pathways, studying co-expression profiles, and identifying com-
mon interaction partners in a human PPI network. All these
approaches were undertaken with human genes associated with
HIV and genes involved in pathways of disease. Two hundred
twenty (220) human pathways involved in disease from the Kyoto
Encyclopedia of Genes and Genomes (KEGG) were evaluated and
statistically compared with HIV host factors. Many tests found
significant associations between gene expression and HIV, and all
test scores were transformed into ranks. Rank combination of
these results led to a final ranking of HIV-associated pathways that
provided insight into AIDS comorbidities, their underlying
molecular mechanisms, and novel potential treatment strategies.
Data fusion or the combination of multiple sources of information
are techniques that have been applied to prioritize genes [18] or
drug candidates [19]. However, the application of these concepts
to pathways is less common. To the best of our knowledge, this is
the first study to combine the rankings of pathways through
different approaches.
Results
Consensus in HIV Host Factors
The HIV host factors identified among different studies are
diverse. Figure 1 illustrates a Venn diagram of host factors
identified from three systematic screening studies [1–3] and from
HIV-human protein interactions reported in the literature [4].
Data from several sources can be merged with either set union or
intersection operations. For the current study, the intersection
approach was taken. As genes from our four sources were not
balanced in terms of representation, the union of these data would
make the results severely biased toward the largest set (HIV
Interaction Database, 1,431 proteins). However, only one gene,
RELA (a component of NF-kB), was consistently identified by all
four sources. Therefore, genes identified by at least three sources
were included for analysis, and twelve (12) host factors met this
criterion (Table 1). These host factors were defined as a ‘core set’
for subsequent analysis in this work, and were referred to as ‘host
factors.’ The degrees (numbers of interactions) of these genes in
HIV-human and human-human protein-protein interactions and
their respective ranks are also illustrated. Most of these host factors
were not ranked highly. The human protein that interacted with
the most HIV proteins was the gene product of MAPK1 (mitogen-
activated protein kinase 1), whereas the human protein that
interacted with the most human proteins was UBC (ubiquitin C).
However, both proteins were not identified by the three systematic
screenings as HIV host factors.
Previous analysis of protein-protein interactions between human
proteins and various viruses has shown that many pathogenic
viruses interact with ‘hubs’ (high degree nodes) in the human
interaction network [13–15]. However, ranking host factors by
their degrees did not reflect this property. Among the 12 host
factors studied, only two (RELA and AKT1, ranked 36.5 and 35,
respectively) were ranked within the top 100 of 11,030 human
proteins with current interaction data available. As for HIV-
human interactions, only CD4 was targeted by multiple HIV
Figure 1. Venn diagram of HIV host factors. The numbers of common host factors reported in one, two, three or four sources are shown on
respective cells. Only 12 host factors (white circle) were reported by more than three studies, and only one was reported in all four sources.
doi:10.1371/journal.pone.0034240.g001
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PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e34240proteins, and CD4 was ranked 6.5 among 1,431 human proteins
with HIV-human interaction data available.
GO Annotation Enrichments of HIV Host Factors
To understand the involvement of HIV host factors in biological
processes, Gene Ontology (GO) annotations (biological processes)
were compiled for host factors and compared to those of the entire
human genome. For HIV host factors, ‘multi-organism process
(GO:0051704)’, ‘immune system process (GO:0002376)’, ‘viral
reproduction (GO:0016032)’, ‘response to stimulus (GO:0050896)’,
and ‘biological regulation (GO:0065007)’ were significantly en-
riched (all with p-values,1610
25, Figure 2). The definition of a
‘multi-organism process’ in Gene Ontology was: ‘Any process in
which anorganism hasan effect on anotherorganism of the same or
different species (http://amigo.geneontology.org/cgi-bin/amigo/
term_details?term=GO:0051704).’ Therefore, genes targeted by
HIVarelikelytobe thoseinvolved inhuman-pathogeninteractions.
The enrichment of ‘immune system process’, ‘viral reproduction’
and ‘biological regulation’ is consistent with the behaviors of HIV
and the consequences of HIV infection. The enrichment of
‘response to stimulus’ reflects the behaviors of cells in response to
the binding or detection of the virus. These results are consistent
with what is currently known about the virus, which includes its
modulation of the immune system and its interference with cellular
processes.
Associations between HIV Host Factors and KEGG
Pathways
There are 220 human pathways available in KEGG. Among
these, 86 are metabolic pathways and the others belong to signaling
pathways or pathways of disease. None of the metabolic pathways
ranks in the top 10 by all four rankings (Supplementary Table S1).
Almost all of the metabolic pathways are ranked in the bottom half
of the list, with the overall pathway (hsa01100: Metabolic Pathway)
ranked last. This suggests that HIV host factors are not greatly
involved in metabolic processes, which is consistent with our GO
enrichment/depletion analysis (Supplementary Table S2). The
association between each pathway and a set of HIV host factors was
evaluated using several approaches. Pathways were then ranked by
statistical tests in comparison with random pathways. The nature of
each approach led to different rankings for these pathways. Six
pathways were ranked in the top 10 in at least three rankings. These
consensus pathways include ‘Pancreatic cancer (hsa05212)’, ‘Small
cell lung cancer (hsa05222)’, ‘Acute myeloid leukemia (hsa05221)’,
‘Adipocytokine signaling pathway (hsa04920)’, ‘B cell receptor
signaling pathway (hsa04662)’, and ‘T cell receptor signaling
pathway (hsa04660)’ (Supplementary Table S1).
To further explore the consensus pathways identified by the
four approaches to analysis, a data fusion method was applied.
The correlations among different rankings were calculated and are
listed in Table 2. Two approaches were highly correlated, namely
‘Common Genes’ and ‘Recovered Interactions.’ The other
correlations were less obvious, suggesting that these approaches
yielded diverse results. In principle, rank combination of
diversified results leads to better rankings [20,21]. Based on these
rank correlations, the ranks resulting from the four analytical
approaches were combined as illustrated in Figure 3. The two
most highly correlated rankings were combined first, as otherwise
they would weigh too heavily when combined with the other
rankings. The resulting three rankings were then combined again,
resulting in the final ranking.
The top 10 KEGG diseases/pathways in the final ranking are
listed in Table 3, along with their ranks and statistical significances
as calculated by the four approaches. The six top-ranked
consensus pathways were still ranked highly in the final ranking.
However, four pathways were promoted by the combined ranking,
namely ‘Chronic myeloid leukemia (hsa05220)’, ‘Toll-like receptor
signaling pathway (hsa04620)’, ‘Chemokine signaling pathway
(hsa04062)’, and ‘Apoptosis (hsa04210)’.
HIV particles must be granted entry into cells for successful
infection and replication. It is thus understandable that ‘Chemo-
kine signaling pathway’ was one of the top 10 pathways associated
with HIV host factors. The glycoproteins gp160, gp120, and gp41
of HIV bind with CD4 and CXCR4/CCR5 on host cells before
gaining entry into T cells. This binding triggers various signals
throughout the cell, affecting the survival and migration of cells.
Three other pathways were involved in sensing and responding
to viral infections, including ‘Toll-like receptor (TLR) signaling
pathway’, ‘T-cell receptor (TCR) signaling pathway’, and ‘B-cell
receptor (BCR) signaling pathway’. Activation of these pathways
leads to immune responses including antigen processing and
presentation, immunoglobulin production, and interferon-mediat-
ed antiviral effects. In some cases, activation of these pathways
may also lead to autoimmunity.
Table 2. Rank correlation coefficients among rankings of pathways identified by our four approaches.
Common Genes Recovered Interactions Co-Expressed Genes Common Interaction Partners
Common Genes
Recovered Interactions 0.9933
Co-Expressed Genes 0.5624 0.5576
Common Interaction Partners 0.5432 0.5398 0.5822
doi:10.1371/journal.pone.0034240.t002
Figure 2. GO distribution. Significantly enriched GO terms between
the human genome (empty bars) and HIV host factors (solid bars) are
reported here. The p-values for these GO terms were all ,1610
25.
doi:10.1371/journal.pone.0034240.g002
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PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e34240Other gene expression-based studies also identified pathways
associated with HIV infection [22,23]. Our findings were
consistent in identifying pathways identified in these studies,
including ‘Apoptosis Pathway’, ‘Cytokine Responses’, and ‘Toll-
like Receptor Pathway’ [22].
The cancers identified in this work were not HIV/AIDS-
defining cancers and were not known to have been caused by
infectious agents. However, various population-based studies have
shown that the risks of contracting many of these cancers are
elevated in people with HIV/AIDS. An epidemiological study in
France showed that the incidence of acute myeloid leukemia
(AML) in HIV/AIDS patients was two-fold higher than that of the
general population [24]. One study in Germany suggested that
long-term immune suppression increased AML risk [25]. The
clinical evidence for associations between chronic myeloid
leukemia (CML) and HIV/AIDS is less clear, though some
studies have suggested that HIV infections and highly active anti-
retroviral therapy (HAART) may increase the risk of CML [26].
Two studies in the United States and one in Denmark showed that
the incidence of lung cancer increases in HIV-infected individuals
[27] and that HIV infection is associated with an increased risk of
lung cancer [28,29]. Two studies in France [30] and Italy [31] also
found that pancreatic cancer deaths were significantly higher in
populations with HIV/AIDS.
The association between HIV and the ‘adipocytokine signaling
pathway’ was less clear. However, HIV protease inhibitors and
other anti-retroviral therapies have been shown to alter human
adipocyte differentiation and metabolism [32,33]. The underlying
mechanism for this lipodystrophy might be due to mitochondrial
toxicity and insulin resistance [34]. This association was noted in
an RNAi systemic screening study [3].
Discussion
Using a set of stringent and conserved host factors, it has been
found that HIV does not always target ‘hubs’ or high-degree nodes
in the human interactome. High-throughput screening of host-
pathogen interactions may lead to interactions with already
promiscuous proteins. Additionally, ‘hubs’ in a network are not
necessarily involved in specific processes. Combining data from
multiple sources reduced the number of false positives. Associa-
tions between a reliable ‘core set’ of HIV host factors and
Figure 3. Rank combination scheme. Four measures were used in
this study to rank KEGG pathways. Based on rank correlation, two
(common genes and recovered HIV interactions) were merged by rank
combination. The resulting three ranks were then combined again
using the same data fusion technique.
doi:10.1371/journal.pone.0034240.g003
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reveal insights into the underlying molecular mechanisms of
pathogenesis and comorbidities.
In conventional pathway enrichment methods (GSEA) all genes
(host factors and genes in the human genome) must be ranked
using a pre-specified criterion. Usually gene expression profiles of
a certain phenotype (such as HIV infection) would be used.
However, using this method, multiple factors or conditions cannot
be considered together. Other than gene expression, the weight of
evidence (number of independent studies reporting the gene being
linked to the disease or condition) and degrees or centralities in
protein-protein interaction networks could also be employed as
ranking criteria. However, most of these criteria are unable to
assign scores to all human genes, and would impact the
calculations of enrichment scores and the ranking of pathways.
Unlike the GSEA method, our method only requires a set of host
factors. Associations between HIV and pathways are dependent
on the set of HIV host factors. This is advantageous in terms of the
computational complexity as the remaining genes in the human
genome can be omitted from further study.
In this work, various cancer pathways were shown to be
significantly associated with HIV. This observation is consistent
with several studies investigating cancer risks in HIV/AIDS
populations [27,30,31]. Why does HIV associate with diverse
types of cancers? HIV is known to integrate its genetic materials
into the host genome, which could be a cause of HIV-defining
carcinomas. The random sites of integration of HIV might corrupt
the expression of tumor-suppresser genes and alter the behaviors
of cells. For other non-HIV-defining cancers, it is recognized that
apoptosis (the killing of damaged cells) [35] and senescence (the
inactivation of damaged cells) [36] play critical roles in
tumorigenesis.
One concern over the associations revealed in this work is
whether highly ranked pathways were simply those with more
genes, as larger pathways may include more host factors by
chance. The KEGG database contains various types of pathways,
including ‘Metabolism’, ‘Genetic Information Processing’, ‘Envi-
ronmental Information Processing’, ‘Cellular Processes’, ‘Organ-
ismal Systems’, and ‘Human Diseases’ [37]. Whether certain types
of pathways would cluster at the top of the ranking may cause
concern for the validity of the ranking results. To address these
issues, the numbers of genes in pathways were plotted against the
ranks of those pathways (Figure 4). The resulting figure illustrates
that ranks are not correlated with the numbers of genes in
pathways. Other than ‘Metabolism’, which tends to rank low, most
pathways do not exhibit obvious trends of clustering.
Many of the host factors studied were significantly involved in
the apoptosis pathway, notably AKT1 and RELA (part of NF-kB).
Apoptosis is a mechanism used by infected cells to control the
spread of pathogens. Interactions between the HIV Tat protein
and AKT1 and RELA inhibit apoptosis, and lead to the survival
and proliferation of cells [38,39]. Activation of NF-kB in turn
activates a number of survival genes. This strategy might help HIV
to spread to other cells. The activation of survival genes might also
inadvertently promote the growth and proliferation of cancer cells.
Several cancer pathways highlighted in this work shared similar
molecular machinery.
The pancreatic cancer pathway was ranked first in the final
ranking. There has been little data reported on the association
between HIV and pancreatic cancer [30,31], which might be due
to the low prevalence of pancreatic cancer in the general
population and its resulting difficulty of study. HIV host factors
involved in the pancreatic cancer pathway (hsa05212) are
highlighted (Figure 5). Many of these genes play important roles
in a central pathway (the EGF/EGFR/JAK1/AKT/NF-kB axis)
that might lead to the survival and proliferation of cancer cells, as
noted above. Additionally, highly active anti-retroviral treatments
(HAART) may also negatively affect the pancreas [40]. The cause
of the increased incidence of pancreatic cancers in HIV/AIDS
populations [30,31] is not clear; it is speculated that the
introduction of HAART significantly prolonged the life-span of
HIV/AIDS patients, which might contribute to increases in
tumor-associated deaths [31].
To further elucidate the interactions between host factors and
pancreatic cancers, 80 mutated genes implicated in pancreatic
cancers were retrieved from a systematic screening survey [41]. A
network of interactions among HIV proteins, host factors, and
mutated genes in pancreatic cancers was constructed (Figure 6).
The resulting network illustrated the fact that HIV host factors do
not interact with mutated pancreatic genes directly; instead, a set
Figure 4. KEGG Pathway categories and ranks. The ranks of KEGG pathways are plotted against the numbers of genes in the pathways.
Pathways are labeled according to their assigned categories on the KEGG website (http://www.genome.jp/kegg/pathway.html).
doi:10.1371/journal.pone.0034240.g004
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Interactions from the HIV-human interaction database revealed
that HIV proteins share more interactions with host factors and
these ‘hubs’, and fewer interactions with genes mutated in
pancreatic cancer. At first glance, these results might suggest that
the association between HIV infection and pancreatic cancer
arises from the ‘common interaction partner’ method used in this
work. However, in the four approaches used to study these data,
the pancreatic cancer pathway ranked 1
st,6
th,8
th, and 1
st,
respectively, and these associations were all statistically significant
(Table 3). Thus, the association was not solely determined by
indirect human protein-protein interactions. The existence of
‘proxy’ genes in the interaction network suggests that HIV
infections and pancreatic mutations might lead to common
outcomes, notably the activation of anti-apoptotic and pro-survival
signaling pathways.
Chronic immune suppression was shown to increase the incidences
of various cancers [25,42]. HIV infection depletes CD4+ T-cells and
macrophages, imposing a great impact on immune system functions.
Recent studies revealed that CD4+ T-cells and macrophages are
Figure 5. HIV host factors in the pancreatic cancer pathway. The pancreatic cancer pathway was reconstructed from Pancreatic Cancer
Pathway (has:05212) in KEGG. Host factors are in red, including AKT1 (PKB/Akt), JAK1 (Jak1), and RELA (NF-kB). HIV protein Tat (in blue) interacted
with AKT1 and NF-kB, activated the two proteins, and led to the expression of anti-apoptotic genes. The parallel solid lines represent the cell
membrane. The dashed line represents the nuclear membrane.
doi:10.1371/journal.pone.0034240.g005
Figure 6. PPI network of HIV proteins, host factors, and genes that are mutated in pancreatic cancer. Connections between host factors
(blue nodes) and mutated genes in pancreatic cancer (red nodes) were primarily relayed by other common interactors (‘hubs’, yellow nodes). HIV
proteins (green nodes) interacted mostly with host factors and hubs.
doi:10.1371/journal.pone.0034240.g006
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prevention and regression of cancers [43]. Without functioning
immune systems and these immune cells, senescent cells promote
tumor growth and metastasis, though the underlying mechanism for
this promotion remains to be elucidated [44].
Notably, several anti-retroviral agents were shown to have anti-
tumor activities, and were used to treat various types of cancers
[45]. Many HIV protease inhibitors also exhibited various degrees
of kinase inhibition activity. For example, saquinavir, ritonavir,
nelfinavir, and amprenavir were all able to inhibit phosphor-Akt
(AKT1 was one of the host factors studied) and interfered with
various signaling pathways. Among these protease inhibitors,
nelfinavir has the most potent anti-cancer activity and was tested
in clinical trials against pancreatic cancer [46]. Computational
modeling and screening of human kinases revealed that nelfinavir
inhibited multiple kinases, and its potent anti-tumor activity might
come from this combined effect [47]. However, the tumor
suppressor protein p21 (CDKN1A) was shown to confer HIV-1
resistance [48]. This and other studies suggest that anti-tumor
drugs, specifically cyclin-dependent kinase (CDK) inhibitors,
might serve as novel HIV/AIDS treatments [49,50].
This work used a combined approach to identify associations
between one specific pathogen (HIV) and human pathways.
Various strategies are possible approaches to refining our method,
such as comparisons of score combination and rank combination
[51], and the use of a rank-score plot to identify the diversity of
rankings and further improve combination results [52]. The
identification of several cancer pathways associated with HIV was
consistent with epidemiological reports of comorbidities and
increased cancer risks in the HIV/AIDS population. The
involvements of host factors in various cancer-related pathways
also suggested the existence of common drugs or treatment
options, as exemplified by HIV protease inhibitors and other anti-
retroviral agents [45], and CDK inhibitors [49,50]. Further
investigations into the targets of anti-tumor drugs and their
relationships with HIV host factors might reveal insights into novel
treatment strategies for both HIV infection and cancers.
Materials and Methods
HIV Host Factors
HIV host factors were collected from the Human, HIV-1
Interaction Database [4] and several systemic screening studies.
Overall, 1998 genes were identified and most (1431) werecontributed
by the HIV Interaction Database. Among these host factors, twelve
(12) were reported by more than three studies and have been used as
the set to be evaluated against the KEGG pathways.
Human, HIV-1 Interaction Data and GO Annotation
Human, HIV-1 protein interactions were retrieved from the
NCBI HIV-1, Human Protein Interaction Database [4]. Gene
Ontology annotations of these human proteins were retrieved
from the NCBI GeneRIF database (ftp://ftp.ncbi.nlm.nih.gov/
gene/DATA/gene2go.gz). GO annotations have been assigned to
GO terms one level below ‘‘Biological Process (GO:0008150)’’
using the ‘‘is_a’’ relationship in the Gene Ontology Database
(revision: 1.2343, date: 24:10:2011). There were 24 terms in this
level. For each term, the statistical significances of the proportional
difference between the human genome and the set of HIV host
factors were evaluated using a 2-sample proportion test.
Human Protein-Protein Interactions
Human protein-protein interaction data were retrieved from the
NCBI Interactions database (ftp://ftp.ncbi.nlm.nih.gov/gene/
GeneRIF/, retrieved on Sep, 28, 2011). Eighty (80) genes mutated
in pancreatic cancer were reported [41] and used to construct a
protein-protein interaction network among HIV, host factors, and
pancreatic cancer. None of these mutated genes overlapped with
the 12 host factors. Protein-protein interaction networks were
constructed and visualized using Cytoscape [53].
KEGG Pathway Mapping
KEGG pathways and the genes that participate in these
pathways were retrieved from the KEGG ftp site (ftp://ftp.
genome.jp/pub/kegg/pathway/) [54]. Several files in the KEGG
ftp site provide mapping between genes and pathways. Entrez
Gene IDs of human targets were used to link HIV proteins to their
respective KEGG pathways.
Evaluation of HIV/KEGG Pathway associations
In this work, four approaches were applied to evaluate
associations between HIV host factors and KEGG pathways.
The rationales and details for applying these approaches are
outlined here.
Common Genes. The first approach counts the number of
genes appearing both in the set of HIV host factors and in
individual pathways. If a pathway includes many HIV host factors,
the association between the pathway and HIV would be highly
significant. However, ranking pathways by the numbers of shared
genes may be misleading. Large pathways with more genes may
include more host factors by chance. Therefore, a bootstrap
method was applied to estimate the distribution of shared gene
numbers in random pathways, and to evaluate the statistical
significance of the pathways. Pathways were ranked by their
statistical significance (z-scores) and not by the numbers of
common genes. The same procedure was applied to all four
approaches. Details of the statistical testing procedures are
described below.
Recovered Interactions. Host factors may contribute in
different ways to virus-human interactions. Recovered interactions
do not count the numbers of common genes, but do count the
numbers of virus-human interactions. For example, two pathways
with the same number of genes may both include three different
host factors; the three host factors in pathway A may include eight
human-virus interactions, and those in pathway B may only
include five interactions. In this example, the association between
HIV and pathway A would be stronger.
Co-expressed Genes. Some genes not in the host factor set
may not have available human-virus interaction data. Co-
expressions of these genes and host factors may provide another
means by which to identify associations. Inference of gene
associations through co-expressions has been widely adopted
[55,56]. Gene expression profiles from BioGPS [57] have been
used to construct co-expressed relationships. For each gene, the
expression levels across various tissue types have been used as the
‘expression profile’ of this particular gene. If more than one probe
mapped to the same gene, the expression levels for these probes
were averaged and assigned to the specific gene. Two genes were
considered to be co-expressed if the Pearson correlation coefficient
of their respective expression profiles across different tissue types
was greater than 0.85.
Common Interaction Partners. The functions of proteins
can be predicted using their connectivity information in protein-
protein interaction networks [58,59]. An association between two
gene sets is considered to be strong if the two sets are connected by
more common interaction partners between them. Common
interaction partners of two genes are gene products that interact
with both of the genes, excluding the two genes themselves (self-
HIV/Human Disease Associations
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were seen as ‘proxies’ or ‘bridges’ between two gene sets, and they
represented indirect interactions between the two gene sets.
Statistical Testing and Rank Combination
For each human KEGG pathway, 1,000 random pathways with
the same numbers of genes were generated. The resulting
distributions were used to evaluate the statistical significances of
HIV-KEGG pathway associations. The means (m) and standard
deviations (s) of the random distributions were calculated. The z-
statistics of HIV host factors compared with these random
pathways were evaluated. Therefore, p-values were estimated
from the z-statistics.
Genes and gene products were ranked by their degrees of
interaction in human protein-protein interaction networks and
human-HIV protein interaction databases. When genes or gene
products had the same degree, an equal and averaged rank was
assigned. For example, if three genes with N interactions were
placed in 7
th,8
th, and 9
th places, then they each received an
averaged rank of 8 (=(7+8+9)/3).
KEGG Pathways were ranked by z-statistics calculated from the
4 measures outlined above: the number of overlapped genes, the
number of HIV interactions, the number of co-expressed genes,
and the number of common interaction partners in the human
interactome. When applicable, rank combination was applied to
merge ranks into a final rank. For example, Pathway A was ranked
2
nd,1 4
th,5
th, and 7
th in 4 rankings, and Pathway B was ranked 8
th,
1
st,3 3
rd, and 2
nd. After rank combination, their rank scores were 7
and 11, respectively. The rank of Pathway A therefore preceded
that of Pathway B.
Supporting Information
Table S1 Rankings of KEGG Pathways by various
approaches and rank combination. Detailed information
for the constructions of rankings by the four approaches and rank
combination are included. For each approach, the means,
standard deviations, z-statistics, p-values and ranks are provided.
Ranks are based on z-statistics. The 220 KEGG pathways were
sorted by combined ranks.
(XLS)
Table S2 Enrichments and depletions of Gene Ontology
biological processes. Proportional differences in GO biological
processes between the human genome and a set of HIV host
factors were tested; z-statistics and p-values are provided. These
GO processes were sorted by z-statistics. GO processes enriched in
HIV host factors were placed at the top.
(XLS)
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